Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 14/20 | 0.49 |
| ▸ | PTGES | O14684 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3276812 | 1.00 | GRM5 (0.49) | GRM5PTGESKCNH2MAP3K14 | |
| SCHEMBL2813710 | 0.86 | GRM5 (0.54) | GRM5 | |
| SCHEMBL3281658 | 0.86 | GRM5 (0.50) | GRM5 | |
| SCHEMBL3277834 | 0.86 | GRM5 (0.50) | GRM5 | |
| SCHEMBL2816086 | 0.86 | GRM5 (0.54) | GRM5 | |
| SCHEMBL2839746 | 0.85 | GRM5 (0.43) | GRM5 | |
| SCHEMBL2842438 | 0.85 | GRM5 (0.43) | GRM5 | |
| SCHEMBL2838365 | 0.85 | GRM5 (0.43) | GRM5 | |
| SCHEMBL2841216 | 0.85 | GRM5 (0.43) | GRM5 | |
| SCHEMBL14734735 | 0.84 | GRM5 (0.44) | GRM5MAP3K14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1877365-B1 | ACETYLENE DERIVATIVES | NOVARTIS AG (CH) | 2010-11-10 | — | — | EP | claimed |
| US-7696379-B2 | Acetylene derivatives | NOVARTIS AG (CH) | 2010-04-13 | — | — | US | claimed |
| EP-2826478-A1 | COMBINATIONS COMPRISING MGLUR MODULATORS FOR THE TREATMENT OF PARKINSON'S DISEASE | Novartis AG (CH) | 2015-01-21 | — | — | EP | disclosed |
| WO-2013131981-A1 | PREDICTIVE MARKERS USEFUL IN THE DIAGNOSIS AND TREATMENT OF FRAGILE X SYNDROME (FXS) | NOVARTIS AG (CH) | 2013-09-12 | — | — | WO | disclosed |
| EP-2563934-A1 | PREDICTIVE MARKERS USEFUL IN THE TREATMENT OF FRAGILE X SYNDROME (FXS) | Novartis AG (CH) | 2013-03-06 | — | — | EP | disclosed |
| US-20130052644-A1 | Predictive Markers Useful in the Treatment of Fragile X Syndrome (FXS) | NOVARTIS AG (CH) | 2013-02-28 | — | — | US | disclosed |
| EP-2320892-A2 | COMBINATION PRODUCTS | Novartis AG (CH) | 2011-05-18 | — | — | EP | disclosed |
| EP-1877365-B1 | ACETYLENE DERIVATIVES | NOVARTIS AG (CH) | 2010-11-10 | — | — | EP | disclosed |
| EP-2211859-A2 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS FOR THE TREATMENT OF PARKINSON'S DISEASE | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| US-20100099682-A1 | ACETYLENE DERIVATIVES | NOVARTIS AG | 2010-04-22 | — | — | US | disclosed |
| US-7696379-B2 | Acetylene derivatives | NOVARTIS AG (CH) | 2010-04-13 | — | — | US | disclosed |
| WO-2010000763-A2 | COMBINATION PRODUCTS | NOVARTIS AG (CH) | 2010-01-07 | — | — | WO | disclosed |
| EP-2069305-A2 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Novartis AG (CH) | 2009-06-17 | — | — | EP | disclosed |
| WO-2009047296-A2 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS FOR THE TREATMENT OP PARKINSON'S DISEASE | NOVARTIS AG (CH) | 2009-04-16 | — | — | WO | disclosed |
| US-20080214673-A1 | Acetylene Derivatives | NOVARTIS AG (CH) | 2008-09-04 | — | — | US | disclosed |
| WO-2008031550-A2 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTANATE RECEPTORS | NOVARTIS AG (CH) | 2008-03-20 | — | — | WO | disclosed |
| EP-1877365-A1 | ACETYLENE DERIVATIVES | Novartis AG (CH) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006114262-A1 | ACETYLENE DERIVATIVES | NOVARTIS AG (CH) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099682-A1 | ACETYLENE DERIVATIVES | NAT1, NAT10, F12 | GRM5 3794/4885PTGES 2653/4885KCNH2 603/4885 |
| US-20080214673-A1 | Acetylene Derivatives | NAT1, NAT10, F12 | GRM5 3794/4885PTGES 2653/4885KCNH2 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.